Moleculin Biotech, Inc. (MBRX) Free cash flow 2016–2025
Moleculin Biotech, Inc. (MBRX) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$22.7MFY2025 · since FY2016: -$3.8M → -$22.7M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$22.7M | +4.8% |
| FY2024 | -$23.9M | -0.7% |
| FY2023 | -$23.7M | +14.4% |
| FY2022 | -$27.7M | -46.1% |
| FY2021 | -$19.0M | -4.5% |
| FY2020 | -$18.1M | -5.2% |
| FY2019 | -$17.3M | -36.7% |
| FY2018 | -$12.6M | -71.7% |
| FY2017 | -$7.4M | -94.2% |
| FY2016 | -$3.8M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice